Literature DB >> 376184

Determination of plasma octopamine and its level in renal disease.

D W Kinniburgh, N D Boyd.   

Abstract

A radioenzymatic assay method for the estimation of octopamine levels in plasma was developed. Preparation of the enzyme, phenylethanolamine-N-methyl transferase, dilution of the plasma sample, preparation of a suitable blank, and the assay conditions were found to have a significant effect on the sensitivity of the assay. Plasma octopamine levels were measured in a population of 33 normal individuals ranging in age from 19 to 94 years. Significantly higher plasma octopamine levels were found in the age group 70-90 years. Excluding those individuals over the age of 70 years, no significant differences in plasma octopamine levels were found for males or females, the range of values was 0 to 0.68 ng per ml, with a mean value of 0.23 ng per ml (n = 25). Examination of plasma octopamine levels in patients with severe renal disease requiring hemoperfusion dialysis, revealed a significantly higher level of plasma octopamine in renal disease (1.9 ng per ml), and an increase in plasma octopamine during dialysis; the mean level post dialysis being 2.7 ng per ml.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376184     DOI: 10.1016/s0009-9120(79)90048-1

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

Review 1.  Trace amine-associated receptors and their ligands.

Authors:  R Zucchi; G Chiellini; T S Scanlan; D K Grandy
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

2.  Plasma catecholamines in hepatic coma and liver cirrhosis: role of octopamine.

Authors:  H Hörtnagl; H Lochs; G Kleinberger; J M Hackl; A F Hammerle; H Binder; F Wewalka
Journal:  Klin Wochenschr       Date:  1981-10-15

3.  Repeated Solid-state Dewetting of Thin Gold Films for Nanogap-rich Plasmonic Nanoislands.

Authors:  Minhee Kang; Sang-Gil Park; Ki-Hun Jeong
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.